معرفی
Mohamed Sherif, MBBCh, is an Adjunct Professor in the Department of Psychiatry at Yale University's School of Medicine. His research focuses on EEG biomarkers and the antidepressant effects of ketamine, particularly in treatment-resistant depression. He holds a MBBCh from Ain-Shams University and an MSc, though the latter's institution is unspecified. Sherif is affiliated with the Schizophrenia Neuropharmacology Research Group (SNRGY) and the VA Connecticut Healthcare System's Treatment-Resistant Depression Clinic.
His work integrates clinical studies and computational modeling to explore ketamine's mechanisms of action at cellular and microcircuit levels. Key collaborators include Deepak Cyril D'Souza, William Lytton, Gordon Shepherd, Patrick Skosnik, Mohini Ranganathan, and Gerard Sanacora. He received a 2-year VA grant to investigate EEG biomarkers predicting ketamine response, aiming to improve treatment monitoring and patient selection.
Awards include the VA New England Healthcare System Career Development Award. His research addresses critical gaps in depression treatment, especially among veterans, leveraging both experimental and computational approaches to advance therapeutic strategies.
